维奈克拉联合地西他滨治疗AML后MRD的预后价值
研究评估老年/不适合强化疗的急性髓系白血病(AML)患者接受10天地西他滨联合维奈克拉一线治疗后,可测量残留病(MRD)阴性状态的预后价值。起始治疗后1、2、4个月MRD阴性均与显著更优的无复发生存(RFS)、无事件生存(EFS)和总生存(OS)相关。
要点
- 10天地西他滨联合维奈克拉一线治疗老年/不适合AML,54%患者达MRD阴性。
- 2个月时MRD阴性者中位OS 25.1个月,持续MRD阳性者仅7.1个月。
- 1、2、4个月MRD阴性均与显著更优的RFS、EFS和OS相关。
核心结论
- 在老年/不适合强化疗的AML患者中,接受10天地西他滨联合维奈克拉一线治疗后,起始治疗1、2、4个月时MRD阴性状态与显著更好的生存相关。
研究设计与样本
- MRD采用多色流式细胞术检测骨髓标本,灵敏度0.1%。
- 该试验在ClinicalTrials.gov注册,注册号NCT03404193。
关键数值与推荐
- MRD状态对生存结局的差异影响在4个月评估时间点仍持续存在。
临床怎么用
- 对于接受10天地西他滨联合维奈克拉一线治疗的老年/不适合AML患者,应在治疗开始后1、2、4个月评估MRD。
- MRD阴性状态可提供预后信息,有助于风险分层和治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Assessment of measurable residual disease (MRD) provides prognostic information in acute myeloid leukemia (AML). However, the utility of MRD with venetoclax-based lower intensity regimens is unknown. We analyzed the prognostic value of achieving a negative MRD in older/"unfit" patients with AML receiving first-line therapy with 10-day decitabine and venetoclax. MRD was evaluated in bone marrow specimens using multicolor flow cytometry (sensitivity 0.1%). Ninety-seven patients achieving either a complete remission (CR) or CR with incomplete hematologic recovery (CRi) or morphologic leukemia-free state were included. Median age was 72 years (interquartile range, 68-78 years), and 64% had adverse-risk AML. Eighty-three patients achieved CR/CRi, and 52 (54%) became MRD negative. Median time to becoming MRD negative was 2.0 months (interquartile range, 0.9-3.1 months). Patients becoming MRD negative by 2 months had longer relapse-free survival (RFS) compared with those remaining MRD positive (median RFS, not reached vs 5.2 months; hazard ratio [HR], 0.31; 95% confidence interval [CI], 0.12-0.78; P = .004), longer event-free survival (EFS) (median EFS, not reached vs 5.8 months; HR, 0.25; 95% CI, 0.12-0.55; P < .001), as well as longer overall survival (OS) (median OS, 25.1 vs 7.1 months; HR, 0.23; 95% CI, 0.11-0.51; P < .001). Patients achieving an MRD-negative CR had longer OS compared with those with an inferior response (median OS, 25.1 vs 11.6 months; HR, 0.33; 95% CI, 0.19-0.58; P < .0005). Patients becoming MRD negative within 1 month had an improved OS compared with MRD-positive patients (median OS, 25.1 vs 3.4 months; HR, 0.15; 95% CI, 0.03-0.64; P < .0001). Differential impact of MRD status on survival outcomes persisted at a later 4-month time point of evaluation. In conclusion, MRD-negative status at 1, 2, and 4 months after starting therapy confers significantly better survival in older/unfit patients with AML receiving first-line therapy with 10-day decitabine and venetoclax. This trial was registered at www.clinicaltrials.gov as #NCT03404193.
引用
- Maiti A, DiNardo CD, Wang SA, et al. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021. PMID: 33792630. doi:10.1182/bloodadvances.2020003717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。